Vaccination News Home Page subscribe Vaccination NewsLetter
http://bmj.com/cgi/content/full/326/7383/257?etoc
| Home | Help | Search/Archive | Feedback | Table of Contents |
|
|||||||||
 Collections under
which this article appears: Family
Planning Drugs:
obstetrics and gynaecology Venous
Thromboembolism Adverse
drug reactions |
Drug points
Kees van Grootheest
Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH 's-Hertogenbosch, Netherlands
Correspondence to: K van Grootheest
ac.vangrootheest@lareb.nl
Our centre, the Dutch spontaneous reporting system for adverse drug reactions, recently received five reports of thromboembolism as a suspected adverse drug reaction to the new oral contraceptive Yasmin (ethinylestradiol and drospirenone).
A 17 year old woman suddenly collapsed and died after taking the contraceptive for six months. Autopsy showed that she had had a massive pulmonary embolism. No obvious risk factors for thromboembolism, such as smoking, a period of long immobilisation, air flights, or concomitant medication, were evident.1 Because she died suddenly no blood sample was taken. Blood taken from her parents did not test positive for any of the known risk factors: concentrations of protein C and antithrombin III were normal. The activated partial thromboplastin time and partial thromboplastin time were normal, and the existence of factor V Leiden mutation was excluded.
A 28 year old woman changed her oral contraceptive from ethinylestradiol with desogestrel (Marvelon) to ethinylestradiol with drospirenone. Four months later she had thrombosis in one leg and was treated with acenocoumarol. Risk factors or concomitant drugs were unknown.
Another patient, a 45 year old woman, had deep vein thrombosis in one leg after taking ethinylestradiol with drospirenone for two months, as did a 50 year old woman who took the contraceptive for three months. A 35 year old woman had pulmonary thrombosis 17 days after she started taking the contraceptive. She had given birth four months earlier.
Ethinylestradiol with drospirenone has been approved as an oral contraceptive in all European Union countries since 2000 and has recently been launched in the United Kingdom.2 The public assessment report of the contraceptive gives only one suspected case of pulmonary embolism but also says that the number of cases in the preregistration studies are too low for a reliable conclusion on this matter.3
The risk of thromboembolism for women using the third generation (combined)
pill has long been debated. Physicians therefore may prefer a new
type of combined pill, like ethinylestradiol with drospirenone,
assuming that these are safer. However, an association of these drugs
with a lower risk of thromboembolism has not been proved by research,
and our cases show that newer contraceptive pills may have a risk of
thromboembolism. At present, insufficient data on the superiority of
ethinylestradiol with drospirenone are available.
Footnotes
Funding: None.
Competing interests: None declared.
References
| 1. | Winkler UH. Oral contraception in women at risk of venous disease. Gynaecol Forum 2001; 6: 23-28. |
| 2. | Sheldon T. Dutch GPs warned against new contraceptive pill.
BMJ 2002; 324: 869 |
| 3. | Official site of Dutch medicines evaluation board. www.cbg-meb.nl/nl/docs/gnsmiddl/par-yasmin.pdf (accessed 21 October 2002). |
© 2003 BMJ
Publishing Group Ltd
Read all Rapid responses
|
|||||||||
|
Collections under
which this article appears:Family
Planning Drugs:
obstetrics and gynaecology Venous
Thromboembolism Adverse
drug reactions |
| Home | Help | Search/Archive | Feedback | Table of Contents |
© 2003 BMJ Publishing
Group Ltd
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.